Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661542 · ClinicalTrials.gov registry record · Phase 1
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1 study, sponsored by Fujifilm Pharmaceuticals U.S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT02661542 is a Phase 1 study that has completed, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 106 participants.
The verdict
NCT02661542, a Phase 1 study, has completed, sponsored by Fujifilm Pharmaceuticals U.S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer. Cohort 2 will include subjects with another tumor type enrolled in the Phase 1 dose-escalation phase who have demonstrated Clinical Benefit by Week 16.
Interventions
- DRUG FF-10502-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2016-01 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02661542
The ClinicalTrials.gov registry entry for NCT02661542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fujifilm Pharmaceuticals U.S.A., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FF-10502-01 is the first listed.
NCT02661542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02661542 about?
NCT02661542 is a clinical study titled "Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas". A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer. Coh...
What is the current status of trial NCT02661542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2016-01. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT02661542?
The interventions under investigation include: FF-10502-01 (DRUG).
Who is sponsoring clinical trial NCT02661542?
This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.